Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Revenue (2022 - 2025)

Stoke Therapeutics has reported Revenue over the past 4 years, most recently at $1.4 million for Q4 2025.

  • For Q4 2025, Revenue fell 93.8% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $184.4 million, up 404.5%, while the annual FY2025 figure was $184.4 million, 404.5% up from the prior year.
  • Revenue for Q4 2025 was $1.4 million at Stoke Therapeutics, down from $10.6 million in the prior quarter.
  • Over five years, Revenue peaked at $158.6 million in Q1 2025 and troughed at $1.4 million in Q4 2025.
  • A 4-year average of $15.4 million and a median of $3.8 million in 2023 define the central range for Revenue.
  • On a YoY basis, Revenue climbed as much as 3661.12% in 2025 and fell as far as 93.8% in 2025.
  • Year by year, Revenue stood at $3.3 million in 2022, then fell by 14.26% to $2.8 million in 2023, then surged by 707.07% to $22.6 million in 2024, then tumbled by 93.8% to $1.4 million in 2025.
  • Business Quant data shows Revenue for STOK at $1.4 million in Q4 2025, $10.6 million in Q3 2025, and $13.8 million in Q2 2025.